Skip to main content

Advertisement

SpringerLink
Log in

Current Insights into the Mechanisms and Development of Treatments for Heavy-Drinking Cigarette Smokers

  • Alcohol (RF Leeman, Section Editor)
  • Published:
Current Addiction Reports Aims and scope Submit manuscript

Abstract

There is a strong association between cigarette smoking and alcohol use at the epidemiological, behavioral, and molecular levels, and this co-use creates substantial impediments to smoking cessation among smokers who are also heavy drinkers. Compared with individuals who only smoke, those who both drink and smoke heavily experience more severe health consequences and have greater difficulty in quitting smoking. During smoking abstinence, greater alcohol use is associated with decreased odds of smoking cessation, and smokers are substantially more likely to experience a smoking lapse during drinking episodes. As heavy-drinking smokers are less responsive to the currently available pharmacological treatments, this subgroup of high-risk substance users possesses a unique clinical profile and treatment needs. Thus, treatment development for heavy-drinking smokers represents a significant and understudied research area within the field of smoking cessation. This review will briefly describe findings from epidemiological, behavioral, and molecular studies illustrating alcohol and tobacco co-use and identify how the behavioral and neurobiological mechanisms underlying the interaction of alcohol and nicotine may inform the development of targeted treatments for this unique population of smokers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance,•• Of major importance

  1. Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of death in the United States, 2000. JAMA. 2004;291:1238–45.

    Article  PubMed  Google Scholar 

  2. World Health Organization. World health statistics 2010. Geneva: World Health Organization; 2010.

    Google Scholar 

  3. Dani JA, Harris RA. Nicotine addiction and comorbidity with alcohol abuse and mental illness. Nat Neurosci. 2005;8:1465–70.

    Article  CAS  PubMed  Google Scholar 

  4. Kalman D, Morissette SB, George TP. Co-morbidity of smoking in patients with psychiatric and substance use disorders. Am J Addict. 2005;14:106–23.

    Article  PubMed Central  PubMed  Google Scholar 

  5. Harrison ELR, Desai RA, McKee SA. Nondaily smoking and alcohol use, hazardous drinking, and alcohol diagnoses among young adults: findings from the NESARC. Alcohol Clin Exp Res. 2008;32:2081–7.

    Article  PubMed Central  PubMed  Google Scholar 

  6. Negri E, Vecchia CL, Franceschi S, Tavani A. Attributable risk for oral cancer in northern Italy. Cancer Epidemiol Biomarkers Prev. 1993;2:189–93.

    CAS  PubMed  Google Scholar 

  7. Durazzo TC, Gazdzinski S, Meyerhoff DJ. The neurobiological and neurocognitive consequences of chronic cigarette smoking in alcohol use disorders. Alcohol Alcohol. 2007;42:174–85.

    Article  CAS  PubMed  Google Scholar 

  8. Pelucchi C, Gallus S, Garavello W, Bosetti C, La Vecchia C. Alcohol and tobacco use, and cancer risk for upper aerodigestive tract and liver. Eur J Cancer Prev. 2008;17:340–4.

    Article  PubMed  Google Scholar 

  9. Prabhu A, Obi KO, Rubenstein JH. The synergistic effects of alcohol and tobacco consumption on the risk of esophageal squamous cell carcinoma: a meta-analysis. Am J Gastroenterol. 2014;109:822–7.

    Article  PubMed  Google Scholar 

  10. Hurt RD, Offord KP, Croghan IT, et al. Mortality following inpatient addictions treatment: role of tobacco use in a community-based cohort. JAMA. 1996;275:1097–103.

    Article  CAS  PubMed  Google Scholar 

  11. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372:793–5.

    Article  CAS  PubMed  Google Scholar 

  12. Litten RZ, Ryan ML, Falk DE, Reilly M, Fertig JB, Koob GF. Heterogeneity of alcohol use disorder: understanding mechanisms to advance personalized treatment. Alcohol Clin Exp Res. 2015;39:579–84.

    Article  PubMed  Google Scholar 

  13. Fucito LM, Park A, Gulliver SB, Mattson ME, Gueorguieva RV, O’Malley SS. Cigarette smoking predicts differential benefit from naltrexone for alcohol dependence. Biol Psychiatry. 2012;72:832–8. A reanalysis of the COMBINE study indicated that individuals with an AUD who were also smokers may have better alcohol treatment outcomes than nonsmokers.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  14. Joseph AM, Willenbring ML, Nugent SM, Nelson DB. A randomized trial of concurrent versus delayed smoking intervention for patients in alcohol dependence treatment. J Stud Alcohol. 2004;65:681–91.

    Article  PubMed  Google Scholar 

  15. Piasecki TM, McCarthy DE, Fiore MC, Baker TB. Alcohol consumption, smoking urge, and the reinforcing effects of cigarettes: an ecological study. Psychol Addict Behav. 2008;22:230–9.

    Article  PubMed  Google Scholar 

  16. Piasecki TM, Jahng S, Wood PK, Robertson BM, Epler AJ, Cronk NJ, et al. The subjective effects of alcohol–tobacco co-use: an ecological momentary assessment investigation. J Abnorm Psychol. 2011;120:557–71.

    Article  PubMed Central  PubMed  Google Scholar 

  17. SAMHSA. Mental Health Services Administration (SAMHSA), 2014. Results from the 2013 National Survey on Drug Use and Health: summary of national findings, NSDUH Series H-48, HHS Publication No. (SMA) 14-4863. Rockv. MD Subst. Abuse Ment. Health Serv. Adm.

  18. Dawson DA. Drinking as a risk factor for sustained smoking. Drug Alcohol Depend. 2000;59:235–49.

    Article  CAS  PubMed  Google Scholar 

  19. Ockene JK, Adams A. Screening and intervention for smoking and alcohol use in primary care settings: similarities, differences, gaps, and challenges. Alcohol Tob. Basic Sci. Clin. Pract. Natl. Inst. Health. 1995;281–94.

  20. Shiffman S, Tindle H, Li X, Scholl S, Dunbar M, Mitchell-Miland C. Characteristics and smoking patterns of intermittent smokers. Exp Clin Psychopharmacol. 2012;20:264–77.

    Article  PubMed Central  PubMed  Google Scholar 

  21. McKee SA, Weinberger AH. How can we use our knowledge of alcohol-tobacco interactions to reduce alcohol use? Annu Rev Clin Psychol. 2013;9:649–74.

    Article  PubMed Central  PubMed  Google Scholar 

  22. Grant BF, Dawson DA, Stinson FS, Chou SP, Dufour MC, Pickering RP. The 12-month prevalence and trends in DSM-IV alcohol abuse and dependence: United States, 1991–1992 and 2001–2002. Drug Alcohol Depend. 2004;74:223–34.

    Article  PubMed  Google Scholar 

  23. Room R. Smoking and drinking as complementary behaviours. Biomed Pharmacother. 2004;58:111–5.

    Article  PubMed  Google Scholar 

  24. Falk DE, Yi H, Hiller-Sturmhofel S. An epidemiologic analysis of co-occurring alcohol and tobacco use and disorders. Alcohol Res Health. 2006;29:162–71.

    PubMed  Google Scholar 

  25. Niaura RS, Rohsenow DJ, Binkoff JA, Monti PM, Pedraza M, Abrams DB. Relevance of cue reactivity to understanding alcohol and smoking relapse. J Abnorm Psychol. 1988;97:133–52.

    Article  CAS  PubMed  Google Scholar 

  26. Tiffany ST. Potential functions of classical conditioning in drug addiction. In: Drummond DC, Tiffany ST, Glautier S, Remington B, editors. Addictive behavior: cue exposure theory and practice. Oxford: Wiley; 1995. p. 47–71.

    Google Scholar 

  27. Perkins KA. Combined effects of nicotine and alcohol on subjective, behavioral and physiological responses in humans. Addict Biol. 1997;2:255–68.

    Article  CAS  PubMed  Google Scholar 

  28. Burton SM, Tiffany ST. The effect of alcohol consumption on craving to smoke. Addiction. 1997;92:15–26.

    Article  CAS  PubMed  Google Scholar 

  29. Sayette MA, Martin CS, Wertz JM, Perrott MA, Peters AR. The effects of alcohol on cigarette craving in heavy smokers and tobacco chippers. Psychol Addict Behav. 2005;19:263–70.

    Article  PubMed Central  PubMed  Google Scholar 

  30. King AC, Epstein AM. Alcohol dose-dependent increases in smoking urge in light smokers. Alcohol Clin Exp Res. 2005;29:547–52.

    Article  PubMed  Google Scholar 

  31. Kouri EM, McCarthy EM, Faust AH, Lukas SE. Pretreatment with transdermal nicotine enhances some of ethanol’s acute effects in men. Drug Alcohol Depend. 2004;75:55–65.

    Article  CAS  PubMed  Google Scholar 

  32. King A, McNamara P, Conrad M, Cao D. Alcohol-induced increases in smoking behavior for nicotinized and denicotinized cigarettes in men and women. Psychopharmacology (Berlin). 2009;207:107–17.

    Article  CAS  Google Scholar 

  33. Epstein AM, Sher TG, Young MA, King AC. Tobacco chippers show robust increases in smoking urge after alcohol consumption. Psychopharmacology (Berlin). 2006;190:321–9.

    Article  CAS  Google Scholar 

  34. King AC, de Wit H, McNamara PJ, Cao D. Rewarding, stimulant, and sedative alcohol responses and relationship to future binge drinking. Arch Gen Psychiatry. 2011;68:389–99.

    Article  PubMed Central  PubMed  Google Scholar 

  35. Roche DJO, Palmeri MD, King AC. Acute alcohol response phenotype in heavy social drinkers is robust and reproducible. Alcohol Clin Exp Res. 2014;38:844–52.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  36. Cooney NL, Litt MD, Cooney JL, Pilkey DT, Steinburg HR, Oncken CA. Alcohol and tobacco cessation in alcohol-dependent smokers: analysis of real-time reports. Psychol Addict Behav. 2007;21:277–86.

    Article  PubMed Central  PubMed  Google Scholar 

  37. Oliver JA, Blank MD, Van Rensburg KJ, MacQueen DA, Brandon TH, Drobes DJ. Nicotine interactions with low-dose alcohol: pharmacological influences on smoking and drinking motivation. J Abnorm Psychol. 2013;122:1154–65.

    Article  PubMed Central  PubMed  Google Scholar 

  38. McKee SA, O’Malley SS, Shi J, Mase T, Krishnan-Sarin S. Effect of transdermal nicotine replacement on alcohol responses and alcohol self-administration. Psychopharmacology (Berlin). 2008;196:189–200.

    Article  CAS  Google Scholar 

  39. McKee SA, Krishnan-Sarin S, Shi J, Mase T, O’Malley SS. Modeling the effect of alcohol on smoking lapse behavior. Psychopharmacology (Berlin). 2006;189:201–10.

    Article  CAS  Google Scholar 

  40. Kahler CW, Metrik J, Spillane NS, Day A, Leventhal AM, McKee SA, et al. Acute effects of low and high dose alcohol on smoking lapse behavior in a laboratory analogue task. Psychopharmacology (Berlin). 2014;231:4649–57.

    Article  CAS  Google Scholar 

  41. Perkins KA, Fonte C, Grobe JE. Sex differences in the acute effects of cigarette smoking on the reinforcing value of alcohol. Behav Pharmacol. 2000;11:63–70.

    Article  CAS  PubMed  Google Scholar 

  42. Barrett SP, Tichauer M, Leyton M, Pihl RO. Nicotine increases alcohol self-administration in non-dependent male smokers. Drug Alcohol Depend. 2006;81:197–204.

    Article  CAS  PubMed  Google Scholar 

  43. Acheson A, Mahler SV, Chi H, de Wit H. Differential effects of nicotine on alcohol consumption in men and women. Psychopharmacology (Berlin). 2006;186:54–63.

    Article  CAS  Google Scholar 

  44. Bujarski S, Hutchison KE, Roche DJO, Ray LA. Factor structure of subjective responses to alcohol in light and heavy drinkers. Alcohol Clin Exp Res. 2015;39:1193–202.

    Article  PubMed  Google Scholar 

  45. de Wit H, Doty P. Preference for ethanol and diazepam in light and moderate social drinkers: a within-subjects study. Psychopharmacology (Berlin). 1994;115:529–38.

    Article  Google Scholar 

  46. Corbin WR, Gearhardt A, Fromme K. Stimulant alcohol effects prime within session drinking behavior. Psychopharmacology (Berlin). 2007;197:327–37.

    Article  CAS  Google Scholar 

  47. De Wit H, Pierri J, Johanson CE. Reinforcing and subjective effects of diazepam in nondrug-abusing volunteers. Pharmacol Biochem Behav. 1989;33:205–13.

    Article  Google Scholar 

  48. Chutuape MAD, De Wit H. Relationship between subjective effects and drug preferences: ethanol and diazepam. Drug Alcohol Depend. 1994;34:243–51.

    Article  CAS  PubMed  Google Scholar 

  49. Perkins KA, Sexton JE, DiMarco A, Grobe JE, Scierka A, Stiller RL. Subjective and cardiovascular responses to nicotine combined with alcohol in male and female smokers. Psychopharmacology (Berlin). 1995;119:205–12.

    Article  CAS  Google Scholar 

  50. Perkins KA, Grobe JE, Fonte C, Goettler J, Caggiula AR, Reynolds WA, et al. Chronic and acute tolerance to subjective, behavioral and cardiovascular effects of nicotine in humans. J Pharmacol Exp Ther. 1994;270:628–38.

    CAS  PubMed  Google Scholar 

  51. Glautier S, Clements K, White JAW, Taylor C, Stolerman IP. Alcohol and the reward value of cigarette smoking. Behav Pharmacol. 1996;7:144–54.

    Article  CAS  PubMed  Google Scholar 

  52. Rose JE, Brauer LH, Behm FM, Cramblett M, Calkins K, Lawhon D. Potentiation of nicotine reward by alcohol. Alcohol Clin Exp Res. 2002;26:1930–1.

    Article  CAS  PubMed  Google Scholar 

  53. Rose J, Brauer L, Behm F, Cramblett M, Calkins K, Lawhon D. Psychopharmacological interactions between nicotine and ethanol. Nicotine Tob Res. 2004;6:133–44.

    Article  CAS  PubMed  Google Scholar 

  54. Madden PA, Heath AC, Starmer GA, Whitfield JB, Martin NG. Alcohol sensitivity and smoking history in men and women. Alcohol Clin Exp Res. 1995;19:1111–20.

    Article  CAS  PubMed  Google Scholar 

  55. Ralevski E, Perry EB, D’Souza DC, Bufis V, Elander J, Limoncelli D, et al. Preliminary findings on the interactive effects of iv ethanol and iv nicotine on human behavior and cognition: a laboratory study. Nicotine Tob Res. 2012;14:596–606.

    Article  CAS  PubMed  Google Scholar 

  56. Michel C, Bättig K. Separate and combined psychophysiological effects of cigarette smoking and alcohol consumption. Psychopharmacology (Berlin). 1989;97:65–73.

    Article  CAS  Google Scholar 

  57. Kerr JS, Sherwood N, Hindmarch I. Separate and combined effects of the social drugs on psychomotor performance. Psychopharmacology (Berlin). 1991;104:113–9.

    Article  CAS  Google Scholar 

  58. Harrison ELR, Hinson RE, McKee SA. Experimenting and daily smokers: episodic patterns of alcohol and cigarette use. Addict Behav. 2009;34:484–6.

    Article  PubMed Central  PubMed  Google Scholar 

  59. Harrison ELR, McKee SA. Non-daily smoking predicts hazardous drinking and alcohol use disorders in young adults in a longitudinal U.S. sample. Drug Alcohol Depend. 2011;118:78–82.

    Article  PubMed Central  PubMed  Google Scholar 

  60. Funk D, Marinelli PW, Le AD. Biological processes underlying co-use of alcohol and nicotine: neuronal mechanisms, cross-tolerance, and genetic factors. Alcohol Res Health. 2006;29:186.

    PubMed  Google Scholar 

  61. King A, McNamara P, Angstadt M, Phan KL. Neural substrates of alcohol-induced smoking urge in heavy drinking nondaily smokers. Neuropsychopharmacology. 2009;35:692–701.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  62. Drews E, Zimmer A. Modulation of alcohol and nicotine responses through the endogenous opioid system. Prog Neurobiol. 2010;90:1–15.

    Article  CAS  PubMed  Google Scholar 

  63. Spanagel R. Alcoholism: a systems approach from molecular physiology to addictive behavior. Physiol Rev. 2009;89:649–705.

    Article  CAS  PubMed  Google Scholar 

  64. Widdowson PS, Holman RB. Ethanol-induced increase in endogenous dopamine release may involve endogenous opiates. J Neurochem. 1992;59:157–63.

    Article  CAS  PubMed  Google Scholar 

  65. Trigo JM, Martin-García E, Berrendero F, Robledo P, Maldonado R. The endogenous opioid system: a common substrate in drug addiction. Drug Alcohol Depend. 2010;108:183–94.

    Article  CAS  PubMed  Google Scholar 

  66. Hendrickson LM, Guildford MJ, Tapper AR. Neuronal nicotinic acetylcholine receptors: common molecular substrates of nicotine and alcohol dependence. Front Psychiatry. 2013;4:29.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  67. Austin AJ, Duka T, Rusted J, Jackson A. Effect of varenicline on aspects of inhibitory control in smokers. Psychopharmacology (Berlin). 2014;231:3771–85.

    Article  CAS  Google Scholar 

  68. Patterson F, Jepson C, Strasser AA, Loughead J, Perkins KA, Gur RC, et al. Varenicline improves mood and cognition during smoking abstinence. Biol Psychiatry. 2009;65:144–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  69. Boettiger CA, Kelley EA, Mitchell JM, D’Esposito M, Fields HL. Now or later? An fMRI study of the effects of endogenous opioid blockade on a decision-making network. Pharmacol Biochem Behav. 2009;93:291–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  70. Grant JE, Odlaug BL, Schreiber LRN, Kim SW. The opiate antagonist, naltrexone, in the treatment of trichotillomania: results of a double-blind, placebo-controlled study. J Clin Psychopharmacol. 2014;34:134–8.

    Article  CAS  PubMed  Google Scholar 

  71. Zhou F-M, Liang Y, Dani JA. Endogenous nicotinic cholinergic activity regulates dopamine release in the striatum. Nat Neurosci. 2001;4:1224–9.

    Article  CAS  PubMed  Google Scholar 

  72. Salamone JD, Correa M. The mysterious motivational functions of mesolimbic dopamine. Neuron. 2012;76:470–85.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  73. Doyon WM, Thomas AM, Ostroumov A, Dong Y, Dani JA. Potential substrates for nicotine and alcohol interactions: a focus on the mesocorticolimbic dopamine system. Biochem Pharmacol. 2013;86:1181–93.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  74. Yang K, Jin G, Wu J. Mysterious α6-containing nAChRs: function, pharmacology, and pathophysiology. Acta Pharmacol Sin. 2009;30:740–51.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  75. De Biasi M, Dani JA. Reward, addiction, withdrawal to nicotine. Annu Rev Neurosci. 2011;34:105–30.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  76. Larsson A, Jerlhag E, Svensson L, Söderpalm B, Engel JA. Is an α-conotoxin MII-sensitive mechanism involved in the neurochemical, stimulatory, and rewarding effects of ethanol? Alcohol. 2004;34:239–50.

    Article  CAS  PubMed  Google Scholar 

  77. Jerlhag E. Role of the subunit composition of central nicotinic acetylcholine receptors for the stimulatory and dopamine-enhancing effects of ethanol. Alcohol Alcohol. 2006;41:486–93.

    Article  CAS  PubMed  Google Scholar 

  78. Liu L, Hendrickson LM, Guildford MJ, Zhao-Shea R, Gardner PD, Tapper AR. Nicotinic acetylcholine receptors containing the α4 subunit modulate alcohol reward. Biol Psychiatry. 2013;73:738–46.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  79. Powers MS, Broderick HJ, Drenan RM, Chester JA. Nicotinic acetylcholine receptors containing α6 subunits contribute to alcohol reward-related behaviours: α6-containing nAChRs contribute to alcohol reward. Genes Brain Behav. 2013;12:543–53.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  80. Hauser SR, Getachew B, Oster SM, Dhaher R, Ding Z-M, Bell RL, et al. Nicotine modulates alcohol-seeking and relapse by alcohol-preferring (P) rats in a time-dependent manner. Alcohol Clin Exp Res. 2012;36:43–54.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  81. Söderpalm B, Ericson M. Neurocircuitry involved in the development of alcohol addiction: the dopamine system and its access points. In: Sommer WH, Spanagel R, editors. Behavioral neurobiology on alcohol addiction. Berlin: Springer; 2011. p. 127–61.

    Chapter  Google Scholar 

  82. Clark A, Little H. Interactions between low concentrations of ethanol and nicotine on firing rate of ventral tegmental dopamine neurones. Drug Alcohol Depend. 2004;75:199–206.

    Article  CAS  PubMed  Google Scholar 

  83. Berrendero F, Robledo P, Trigo JM, Martín-García E, Maldonado R. Neurobiological mechanisms involved in nicotine dependence and reward: participation of the endogenous opioid system. Neurosci Biobehav Rev. 2010;35:220–31.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  84. Berridge KC, Robinson TE, Aldridge JW. Dissecting components of reward: “liking”, “wanting”, and learning. Curr Opin Pharmacol. 2009;9:65–73.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  85. Olive MF, Koenig HN, Nannini MA, Hodge CW. Stimulation of endorphin neurotransmission in the nucleus accumbens by ethanol, cocaine, and amphetamine. J Neurosci Off J Soc Neurosci. 2001;21:RC184.

    CAS  Google Scholar 

  86. Nestler EJ. Is there a common molecular pathway for addiction? Nat Neurosci. 2005;8:1445–9.

    Article  CAS  PubMed  Google Scholar 

  87. Herz A. Endogenous opioid systems and alcohol addiction. Psychopharmacology (Berlin). 1997;129:99–111.

    Article  CAS  Google Scholar 

  88. Gonzales RA, Weiss F. Suppression of ethanol-reinforced behavior by naltrexone is associated with attenuation of the ethanol-induced increase in dialysate dopamine levels in the nucleus accumbens. J Neurosci. 1998;18:10663–71.

    CAS  PubMed  Google Scholar 

  89. Hall FS, Sora I, Uhl GR. Ethanol consumption and reward are decreased in μ-opiate receptor knockout mice. Psychopharmacology (Berlin). 2001;154:43–9.

    Article  CAS  Google Scholar 

  90. Marty MA, Erwin VG, Cornell K, Zgombick JM. Effects of nicotine on β-endorphin, αMSH, and ACTH secretion by isolated perfused mouse brains and pituitary glands, in vitro. Pharmacol Biochem Behav. 1985;22:317–25.

    Article  CAS  PubMed  Google Scholar 

  91. Dhatt RK, Gudehithlu KP, Wemlinger TA, Tejwani GA, Neff NH, Hadjiconstantinou M. Preproenkephalin mRNA and methionine-enkephalin content are increased in mouse striatum after treatment with nicotine. J Neurochem. 1995;64:1878–83.

    Article  CAS  PubMed  Google Scholar 

  92. Gudehithlu KP, Duchemin A-M, Tejwani GA, Neff NH, Hadjiconstantinou M. Nicotine-induced changes of brain β-endorphin. Neuropeptides. 2012;46:125–31.

    Article  CAS  PubMed  Google Scholar 

  93. Tanda G, Di Chiara G. A dopamine-mu1 opioid link in the rat ventral tegmentum shared by palatable food (Fonzies) and non-psychostimulant drugs of abuse. Eur J Neurosci. 1998;10:1179–87.

    Article  CAS  PubMed  Google Scholar 

  94. Maisonneuve IM, Glick SD. (+/−)Cyclazocine blocks the dopamine response to nicotine. Neuroreport. 1999;10:693–6.

    Article  CAS  PubMed  Google Scholar 

  95. Rezayof A, Nazari-Serenjeh F, Zarrindast M-R, Sepehri H, Delphi L. Morphine-induced place preference: involvement of cholinergic receptors of the ventral tegmental area. Eur J Pharmacol. 2007;562:92–102.

    Article  CAS  PubMed  Google Scholar 

  96. Zarrindast M-R, Faraji N, Rostami P, Sahraei H, Ghoshouni H. Cross-tolerance between morphine- and nicotine-induced conditioned place preference in mice. Pharmacol Biochem Behav. 2003;74:363–9.

    Article  CAS  PubMed  Google Scholar 

  97. Liu X, Palmatier MI, Caggiula AR, Sved AF, Donny EC, Gharib M, et al. Naltrexone attenuation of conditioned but not primary reinforcement of nicotine in rats. Psychopharmacology (Berlin). 2008;202:589–98.

    Article  CAS  Google Scholar 

  98. Corrigall WA, Coen KM, Adamson KL, Chow BLC, Zhang J. Response of nicotine self-administration in the rat to manipulations of mu-opioid and γ-aminobutyric acid receptors in the ventral tegmental area. Psychopharmacology (Berlin). 2000;149:107–14.

    Article  CAS  Google Scholar 

  99. DeNoble VJ, Mele PC. Intravenous nicotine self-administration in rats: effects of mecamylamine, hexamethonium and naloxone. Psychopharmacology (Berlin). 2005;184:266–72.

    Article  CAS  Google Scholar 

  100. Wee S, Koob GF. The role of the dynorphin–κ opioid system in the reinforcing effects of drugs of abuse. Psychopharmacology (Berlin). 2010;210:121–35.

    Article  CAS  Google Scholar 

  101. Jackson KJ, McLaughlin JP, Carroll FI, Damaj MI. Effects of the kappa opioid receptor antagonist, norbinaltorphimine, on stress and drug-induced reinstatement of nicotine-conditioned place preference in mice. Psychopharmacology (Berlin). 2012;226:763–8.

    Article  CAS  Google Scholar 

  102. Shippenberg TS. The dynorphin/kappa opioid receptor system: a new target for the treatment of addiction and affective disorders? Neuropsychopharmacology. 2009;34:247.

    Article  CAS  PubMed  Google Scholar 

  103. Hymowitz N, Cummings KM, Hyland A, Lynn WR, Pechacek TF, Hartwell TD. Predictors of smoking cessation in a cohort of adult smokers followed for five years. Tob Control. 1997;6:S57.

    Article  PubMed Central  PubMed  Google Scholar 

  104. Kahler CW, Spillane NS, Metrik J. Alcohol use and initial smoking lapses among heavy drinkers in smoking cessation treatment. Nicotine Tob Res. 2010;12:781–5.

    Article  PubMed Central  PubMed  Google Scholar 

  105. Kahler CW, Metrik J, LaChance HR, Ramsey SE, Abrams DB, Monti PM, et al. Addressing heavy drinking in smoking cessation treatment: a randomized clinical trial. J Consult Clin Psychol. 2008;76:852–62.

    Article  PubMed Central  PubMed  Google Scholar 

  106. Toll BA, Cummings KM, O’Malley SS, Carlin-Menter S, McKee SA, Hyland A, et al. Tobacco Quitlines need to assess and intervene with callers’ hazardous drinking. Alcohol Clin Exp Res. 2012;36:1653–8.

    Article  PubMed Central  PubMed  Google Scholar 

  107. Brandon TH, Tiffany ST, Obremski KM, Baker TB. Postcessation cigarette use: the process of relapse. Addict Behav. 1990;15:105–14.

    Article  CAS  PubMed  Google Scholar 

  108. Kenford SL, Fiore MC, Jorenby DE, Smith SS, Wetter D, Baker TB. Predicting smoking cessation: who will quit with and without the nicotine patch. JAMA. 1994;271:589–94.

    Article  CAS  PubMed  Google Scholar 

  109. Garvey AJ, Bliss RE, Hitchcock JL, Heinold JW, Rosner B. Predictors of smoking relapse among self-quitters: a report from the normative aging study. Addict Behav. 1992;17:367–77.

    Article  CAS  PubMed  Google Scholar 

  110. Shiffman S, Hickcox M, Paty JA, Gnys M, Kassel JD, Richards TJ. Progression from a smoking lapse to relapse: prediction from abstinence violation effects, nicotine dependence, and lapse characteristics. J Consult Clin Psychol. 1996;64:993–1002.

    Article  CAS  PubMed  Google Scholar 

  111. Shiffman S, Ferguson SG, Gwaltney CJ. Immediate hedonic response to smoking lapses: relationship to smoking relapse, and effects of nicotine replacement therapy. Psychopharmacology (Berlin). 2006;184:608–18.

    Article  CAS  Google Scholar 

  112. Shiffman S. A cluster-analytic classification of smoking relapse episodes. Addict Behav. 1986;11:295–307.

    Article  CAS  PubMed  Google Scholar 

  113. Shiffman S, Paty JA, Gnys M, Kassel JA, Hickcox M. First lapses to smoking: within-subjects analysis of real-time reports. J Consult Clin Psychol. 1996;64:366–79.

    Article  CAS  PubMed  Google Scholar 

  114. Littleton J, Barron S, Prendergast M, Nixon SJ. Smoking kills (alcoholics)! Shouldn’t we do something about it? Alcohol Alcohol. 2007;42:167–73.

    Article  CAS  PubMed  Google Scholar 

  115. Clinical Practice Guideline Treating Tobacco Use and Dependence 2008 Update Panel, Liaisons, and Staff. A clinical practice guideline for treating tobacco use and dependence: 2008 update. A U.S. Public Health Service report. Am J Prev Med. 2008;35:158–76.

    Article  Google Scholar 

  116. Leeman RF, Huffman CJ, O’Malley SS. Alcohol history and smoking cessation in nicotine replacement therapy, bupropion sustained release and varenicline trials: a review. Alcohol Alcohol. 2007;42:196–206.

    Article  PubMed Central  PubMed  Google Scholar 

  117. Leeman RF, McKee SA, Toll BA, Krishnan-Sarin S, Cooney JL, Makuch RW, et al. Risk factors for treatment failure in smokers: relationship to alcohol use and to lifetime history of an alcohol use disorder. Nicotine Tob Res. 2008;10:1793.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  118. Toll BA, Martino S, O’Malley SS, Fucito LM, McKee SA, Kahler CW, et al. A randomized trial for hazardous drinking and smoking cessation for callers to a quitline. J Consult Clin Psychol. 2015;83:445–54. This study demonstrated that a behavioral intervention via telephone quitline that included both alcohol and tobacco counseling was more effective in producing smoking abstinence in heavy drinking smokers than tobacco-only counseling.

    Article  PubMed  Google Scholar 

  119. Fridberg DJ, Cao D, King AC. Integrating alcohol response feedback in a brief intervention for young adult heavy drinkers who smoke: a pilot study. Drug Alcohol Depend. 2015;155:293–7. This study indicated that a behavioral intervention that included personalized feedback on how an individual’s subjective response to alcohol may increase future risk for AUD was more effective than standard alcohol brief interventions in reducing drinking and smoking behavior in heavy drinking smokers.

    Article  PubMed  Google Scholar 

  120. Wiers RW, Eberl C, Rinck M, Becker ES, Lindenmeyer J. Retraining automatic action tendencies changes alcoholic patients’ approach bias for alcohol and improves treatment outcome. Psychol Sci. 2011;22:490–7.

    Article  PubMed  Google Scholar 

  121. Fiore M. Treating tobacco use and dependence: 2008 update: clinical practice guideline. Rockville: Diane Publishing; 2008.

    Google Scholar 

  122. Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, et al. Varenicline Phase 3 Study Group: efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006;296:56–63.

    Article  CAS  PubMed  Google Scholar 

  123. Oncken C, Gonzales D, Nides M, et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med. 2006;166:1571–7.

    Article  CAS  PubMed  Google Scholar 

  124. Williams KE, Reeves KR, Jr CBB, Pennington AM, Gong J. A double-blind study evaluating the long-term safety of varenicline for smoking cessation. Curr Med Res Opin. 2007;23:793–801.

    Article  CAS  PubMed  Google Scholar 

  125. Mills EJ, Wu P, Lockhart I, Thorlund K, Puhan M, Ebbert JO. Comparisons of high-dose and combination nicotine replacement therapy, varenicline, and bupropion for smoking cessation: a systematic review and multiple treatment meta-analysis. Ann Med. 2012;44:588–97.

    Article  CAS  PubMed  Google Scholar 

  126. Mihalak KB. Varenicline is a partial agonist at α4beta2 and a full agonist at α7 neuronal nicotinic receptors. Mol Pharmacol. 2006;70:801–5.

    Article  CAS  PubMed  Google Scholar 

  127. Rollema H, Chambers LK, Coe JW, Glowa J, Hurst RS, Lebel LA, et al. Pharmacological profile of the α4β2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology. 2007;52:985–94.

    Article  CAS  PubMed  Google Scholar 

  128. Coe JW, Brooks PR, Vetelino MG, Wirtz MC, Arnold EP, Huang J, et al. Varenicline: an α4β2 nicotinic receptor partial agonist for smoking cessation. J Med Chem. 2005;48:3474–7.

    Article  CAS  PubMed  Google Scholar 

  129. Picciotto MR, Zoli M, Rimondini R, Léna C, Marubio LM, Pich EM, et al. Acetylcholine receptors containing the β2 subunit are involved in the reinforcing properties of nicotine. Nature. 1998;391:173–7.

    Article  CAS  PubMed  Google Scholar 

  130. Tapper AR, McKinney SL, Nashmi R, Schwarz J, Deshpande P, Labarca C, et al. Nicotine activation of α4* receptors: sufficient for reward, tolerance, and sensitization. Science. 2004;306:1029–32.

    Article  CAS  PubMed  Google Scholar 

  131. Biala G, Staniak N, Budzynska B. Effects of varenicline and mecamylamine on the acquisition, expression, and reinstatement of nicotine-conditioned place preference by drug priming in rats. Naunyn Schmiedeberg’s Arch Pharmacol. 2010;381:361–70.

    Article  CAS  Google Scholar 

  132. Sanjakdar SS, Maldoon PP, Marks MJ, Brunzell DH, Maskos U, McIntosh JM, et al. Differential roles of α6β2* and α4β2* neuronal nicotinic receptors in nicotine-and cocaine-conditioned reward in mice. Neuropsychopharmacology. 2015;40:350–60.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  133. Ashare RL, Tang KZ, Mesaros AC, Blair IA, Leone F, Strasser AA. Effects of 21 days of varenicline versus placebo on smoking behaviors and urges among non-treatment seeking smokers. J Psychopharmacol. 2012;26:1383–90.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  134. Ray LA, Lunny K, Bujarski S, Moallem N, Krull JL, Miotto K. The effects of varenicline on stress-induced and cue-induced craving for cigarettes. Drug Alcohol Depend. 2013;131:136–42.

    Article  CAS  PubMed  Google Scholar 

  135. Brandon TH, Drobes DJ, Unrod M, Heckman BW, Oliver JA, Roetzheim RC, et al. Varenicline effects on craving, cue reactivity, and smoking reward. Psychopharmacology (Berlin). 2011;218:391–403.

    Article  CAS  Google Scholar 

  136. Franklin T, Wang Z, Suh JJ, Hazan R, Cruz J, Li Y, et al. Effects of varenicline on smoking cue-triggered neural and craving responses. Arch Gen Psychiatry. 2011;68:516.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  137. McKee SA, Weinberger AH, Shi J, Tetrault J, Coppola S. Developing and validating a human laboratory model to screen medications for smoking cessation. Nicotine Tob Res. 2012;14:1362–71.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  138. McClure EA, Vandrey RG, Johnson MW, Stitzer ML. Effects of varenicline on abstinence and smoking reward following a programmed lapse. Nicotine Tob Res. 2013;15:139–48.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  139. Patterson F, Jepson C, Loughead J, Perkins K, Strasser AA, Siegel S, et al. Working memory deficits predict short-term smoking resumption following brief abstinence. Drug Alcohol Depend. 2010;106:61–4.

    Article  PubMed Central  PubMed  Google Scholar 

  140. Rhodes JD, Hawk LW, Ashare RL, Schlienz NJ, Mahoney MC. The effects of varenicline on attention and inhibitory control among treatment-seeking smokers. Psychopharmacology (Berlin). 2012;223:131–8.

    Article  CAS  Google Scholar 

  141. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2012;4, CD006103.

    PubMed  Google Scholar 

  142. Hendrickson LM, Zhao-Shea R, Pang X, Gardner PD, Tapper AR. Activation of 4* nAChRs is necessary and sufficient for varenicline-induced reduction of alcohol consumption. J Neurosci. 2010;30:10169–76.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  143. Gotti C, Guiducci S, Tedesco V, Corbioli S, Zanetti L, Moretti M, et al. Nicotinic acetylcholine receptors in the mesolimbic pathway: primary role of ventral tegmental area 6 2* receptors in mediating systemic nicotine effects on dopamine release, locomotion, and reinforcement. J Neurosci. 2010;30:5311–25.

    Article  CAS  PubMed  Google Scholar 

  144. Lê AD, Corrigall WA, Harding JW, Juzytsch W, Li TK. Involvement of nicotinic receptors in alcohol self-administration. Alcohol Clin Exp Res. 2000;24:155–63.

    Article  PubMed  Google Scholar 

  145. Larsson A, Svensson L, Söderpalm B, Engel JA. Role of different nicotinic acetylcholine receptors in mediating behavioral and neurochemical effects of ethanol in mice. Alcohol. 2002;28:157–67.

    Article  CAS  PubMed  Google Scholar 

  146. Ericson M, Molander A, Löf E, Engel JA, Söderpalm B. Ethanol elevates accumbal dopamine levels via indirect activation of ventral tegmental nicotinic acetylcholine receptors. Eur J Pharmacol. 2003;467:85–93.

    Article  CAS  PubMed  Google Scholar 

  147. Löf E, Olausson P, DeBejczy A, Stomberg R, McIntosh JM, Taylor JR, et al. Nicotinic acetylcholine receptors in the ventral tegmental area mediate the dopamine activating and reinforcing properties of ethanol cues. Psychopharmacology (Berlin). 2007;195:333–43.

    Article  CAS  Google Scholar 

  148. Chatterjee S, Steensland P, Simms JA, Holgate J, Coe JW, Hurst RS, et al. Partial agonists of the α3β4* neuronal nicotinic acetylcholine receptor reduce ethanol consumption and seeking in rats. Neuropsychopharmacology. 2011;36:603–15.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  149. Hendrickson LM, Gardner P, Tapper AR. Nicotinic acetylcholine receptors containing the α4 subunit are critical for the nicotine-induced reduction of acute voluntary ethanol consumption. Channels. 2011;5:124–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  150. McKee SA, Harrison ELR, O’Malley SS, Krishnan-Sarin S, Shi J, Tetrault JM, et al. Varenicline reduces alcohol self-administration in heavy-drinking smokers. Biol Psychiatry. 2009;66:185–90.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  151. Fucito LM, Toll BA, Wu R, Romano DM, Tek E, O’Malley SS. A preliminary investigation of varenicline for heavy drinking smokers. Psychopharmacology (Berlin). 2011;215:655–63.

    Article  CAS  Google Scholar 

  152. Mitchell JM, Teague CH, Kayser AS, Bartlett SE, Fields HL. Varenicline decreases alcohol consumption in heavy-drinking smokers. Psychopharmacology (Berlin). 2012;223:299–306.

    Article  CAS  Google Scholar 

  153. Litten RZ, Ryan ML, Fertig JB, Falk DE, Johnson B, Dunn KE, et al. A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence. J Addict Med. 2013;7:277–86. This study was one of the first clinical trials designed to examine varenicline as a treatment for AUD, finding that varenicline (vs. placebo) was effective in reducing heavy drinking days and alcohol craving.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  154. Schacht JP, Anton RF, Randall PK, Li X, Henderson S, Myrick H. Varenicline effects on drinking, craving and neural reward processing among non-treatment-seeking alcohol-dependent individuals. Psychopharmacology (Berlin). 2014;231:3799–807.

    Article  CAS  Google Scholar 

  155. McKee SA, Young-Wolff KC, Harrison ELR, Cummings KM, Borland R, Kahler CW, et al. Longitudinal associations between smoking cessation medications and alcohol consumption among smokers in the International Tobacco Control Four Country survey. Alcohol Clin Exp Res. 2013;37:804–10. This longitudinal, epidemiological study in almost five thousand smokers indicated that patients taking varenicline for smoking cessation were more likely to reduce drinking than patients taking nicotine replacement therapy or no medication.

    Article  PubMed Central  PubMed  Google Scholar 

  156. Childs E, Roche DJO, King AC, de Wit H. Varenicline potentiates alcohol-induced negative subjective responses and offsets impaired eye movements: varenicline effects on alcohol responses. Alcohol Clin Exp Res. 2012;36:906–14.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  157. Vatsalya V, Gowin JL, Schwandt ML, Momenan R, Coe MA, Cooke ME, et al. Effects of varenicline on neural correlates of alcohol salience in heavy drinkers. Int J Neuropsychopharmacol. 2015;18(12).

  158. Plebani JG, Lynch KG, Rennert L, Pettinati HM, O’Brien CP, Kampman KM. Results from a pilot clinical trial of varenicline for the treatment of alcohol dependence. Drug Alcohol Depend. 2013;133:754–8.

    Article  CAS  PubMed  Google Scholar 

  159. Bhutada P, Mundhada Y, Ghodki Y, Dixit P, Umathe S, Jain K. Acquisition, expression, and reinstatement of ethanol-induced conditioned place preference in mice: effects of exposure to stress and modulation by mecamylamine. J Psychopharmacol. 2012;26:315–23.

    Article  CAS  PubMed  Google Scholar 

  160. Chi H, de Wit H. Mecamylamine attenuates the subjective stimulant-like effects of alcohol in social drinkers. Alcohol Clin Exp Res. 2003;27:780–6.

    Article  CAS  PubMed  Google Scholar 

  161. Falk DE, Castle I-JP, Ryan M, Fertig J, Litten RZ. Moderators of varenicline treatment effects in a double-blind, placebo-controlled trial for alcohol dependence: an exploratory analysis. J Addict Med. 2015;9:296–303. In a secondary analysis of 153, this study showed that patients who reduced their cigarette smoking behavior had better alcohol treatment outcomes with varenicline than those who did not decrease their number of cigarettes per day.

    Article  CAS  PubMed  Google Scholar 

  162. Rösner S, Hackl-Herrwerth A, Leucht S, Vecchi S, Srisurapanont M, Soyka M. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev. 2010; CD001867.

  163. Anton RF, Moak DH, Waid LR, Latham PK, Malcolm RJ, Dias JK. Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial. Am J Psychiatry. 1999;156:1758–64.

    CAS  PubMed  Google Scholar 

  164. Ray LA, Krull JL, Leggio L. The effects of naltrexone among alcohol non-abstainers: results from the COMBINE study. Front Psychiatry. 2010;1.

  165. Kiefer F, Jahn H, Tarnaske T, Helwig H, Briken P, Holzbach R, et al. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry. 2003;60:92–9.

    Article  CAS  PubMed  Google Scholar 

  166. Guardia J, Caso C, Arias F, Gual A, Sanahuja J, Ramírez M, et al. A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol-dependence disorder: results from a multicenter clinical trial. Alcohol Clin Exp Res. 2002;26:1381–7.

    Article  CAS  PubMed  Google Scholar 

  167. Volpicelli JR, Alterman AI, Hayashida M, O’Brien CP. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry. 1992;49:876–80.

    Article  CAS  PubMed  Google Scholar 

  168. Latt NC, Jurd S, Houseman J, Wutzke SE. Naltrexone in alcohol dependence: a randomised controlled trial of effectiveness in a standard clinical setting. Med J Aust. 2002;176:530–4.

    PubMed  Google Scholar 

  169. Chick J, Anton R, Checinski K, Croop R, Drummond DC, Farmer R, et al. A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol Alcohol. 2000;35:587–93.

    Article  CAS  PubMed  Google Scholar 

  170. King A, de Wit H, Riley R, Cao D, Niaura R, Hatsukami D. Efficacy of naltrexone in smoking cessation: a preliminary study and an examination of sex differences. Nicotine Tob Res. 2006;8:671–82.

    Article  CAS  PubMed  Google Scholar 

  171. King AC, Cao D, O’Malley SS, Kranzler HR, Cai X, deWit H, et al. Effects of naltrexone on smoking cessation outcomes and weight gain in nicotine-dependent men and women. J Clin Psychopharmacol. 2012;32:630–6.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  172. Covey LS, Glassman AH, Stetner F. Naltrexone effects on short-term and long-term smoking cessation. J Addict Dis. 1999;18:31–40.

    Article  CAS  PubMed  Google Scholar 

  173. O’Malley SS, Cooney JL, Krishnan-Sarin S, et al. A controlled trial of naltrexone augmentation of nicotine replacement therapy for smoking cessation. Arch Intern Med. 2006;166:667–74.

    Article  PubMed  Google Scholar 

  174. Toll BA, White M, Wu R, Meandzija B, Jatlow P, Makuch R, et al. Low-dose naltrexone augmentation of nicotine replacement for smoking cessation with reduced weight gain: a randomized trial. Drug Alcohol Depend. 2010;111:200–6.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  175. Weerts EM, Kim YK, Wand GS, Dannals RF, Lee JS, Frost JJ, et al. Differences in δ- and μ-opioid receptor blockade measured by positron emission tomography in naltrexone-treated recently abstinent alcohol-dependent subjects. Neuropsychopharmacology. 2008;33:653–65.

    Article  CAS  PubMed  Google Scholar 

  176. King AC, Cao D, Zhang L, O’Malley SS. Naltrexone reduction of long-term smoking cessation weight gain in women but not men: a randomized controlled trial. Biol Psychiatry. 2013;73:924–30.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  177. Koegelenberg CF, Noor F, Bateman ED, van Zyl-Smit RN, Bruning A, O’Brien JA, et al. Efficacy of varenicline combined with nicotine replacement therapy vs varenicline alone for smoking cessation: a randomized clinical trial. JAMA. 2014;312:155–61.

    Article  PubMed  CAS  Google Scholar 

  178. Krishnan-Sarin S, Meandzija B, O’Malley S. Naltrexone and nicotine patch in smoking cessation: a preliminary study. Nicotine Tob Res. 2003;5:851–7.

    Article  PubMed  Google Scholar 

  179. David SP, Lancaster T, Stead LF, Evins AE, Prochaska JJ. Opioid antagonists for smoking cessation. Cochrane Database Syst Rev. 2013;6, CD003086. John Wiley & Sons, Ltd.

    PubMed Central  PubMed  Google Scholar 

  180. Ray LA, Miranda R, Kahler CW, Leventhal AM, Monti PM, Swift R, et al. Pharmacological effects of naltrexone and intravenous alcohol on craving for cigarettes among light smokers: a pilot study. Psychopharmacology (Berlin). 2007;193:449–56.

    Article  CAS  Google Scholar 

  181. King AC, Meyer PJ. Naltrexone alteration of acute smoking response in nicotine-dependent subjects. Pharmacol Biochem Behav. 2000;66:563–72.

    Article  CAS  PubMed  Google Scholar 

  182. Epstein AM, King AC. Naltrexone attenuates acute cigarette smoking behavior. Pharmacol Biochem Behav. 2004;77:29–37.

    Article  CAS  PubMed  Google Scholar 

  183. Fridberg DJ, Cao D, Grant JE, King AC. Naltrexone improves quit rates, attenuates smoking urge, and reduces alcohol use in heavy drinking smokers attempting to quit smoking. Alcohol Clin Exp Res. 2014;38:2622–9. This secondary analysis of a smoking cessation clinical trial (171) suggested that naltrexone may be more effective in reducing smoking and drinking behavior in heavy drinking smokers than light or nondrinking smokers.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  184. O’Malley SS, Krishnan-Sarin S, McKee SA, Leeman RF, Cooney NL, Meandzija B, et al. Dose-dependent reduction of hazardous alcohol use in a placebo-controlled trial of naltrexone for smoking cessation. Int J Neuropsychopharmacol. 2009;12:589–97.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  185. King A, Cao D, Vanier C, Wilcox T. Naltrexone decreases heavy drinking rates in smoking cessation treatment: an exploratory study. Alcohol Clin Exp Res. 2009;33:1044–50.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  186. Mattson ME, Litten RZ. Combining treatments for alcoholism: why and how? J Stud Alcohol Suppl. 2005;8–16.

  187. Roche DJO, Bujarski S, Hartwell E, Green R, Ray LA. Combined varenicline and naltrexone treatment reduces smoking topography intensity in heavy-drinking smokers. Pharmacol Biochem Behav. 2015;134:92–8. This laboratory study in the same sample as 188 demonstrated that the combination of varenicline and naltrexone was more effective than either medication alone and placebo in decreasing smoking intensity as measured by smoking topography.

    Article  CAS  PubMed  Google Scholar 

  188. Ray LA, Courtney KE, Ghahremani DG, Miotto K, Brody A, London ED. Varenicline, low dose naltrexone, and their combination for heavy-drinking smokers: human laboratory findings. Psychopharmacology (Berlin). 2014;231:3843–53. This laboratory study was the first to report that the combination of varenicline and naltrexone may be more effective than either medication alone and placebo in reducing alcohol and cigarette craving, subjective response, and daily use.

    Article  CAS  Google Scholar 

  189. Ray LA, Courtney KE, Ghahremani DG, Miotto K, Brody A, London ED. Varenicline, naltrexone, and their combination for heavy-drinking smokers: preliminary neuroimaging findings. Am J Drug Alcohol Abuse. 2015;41:35–44.

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychology, University of California, Los Angeles, Los Angeles, CA, 90095, USA

    Daniel J. O. Roche, Lara A. Ray & Megan M. Yardley

  2. Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, CA, 90095, USA

    Lara A. Ray

  3. Department of Psychiatry and Behavioral Neuroscience, University of Chicago, 5841 S. Maryland Avenue (MC-3077), Chicago, IL, 60637, USA

    Andrea C. King

Authors
  1. Daniel J. O. Roche
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lara A. Ray
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Megan M. Yardley
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Andrea C. King
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrea C. King.

Ethics declarations

Conflict of Interest

Daniel Roche, Megan Yardley, and Andrea King declare that they have no conflict of interest.

Lara Ray has received medication from Pfizer and Medicinova and has consulted for GSK.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Alcohol

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Roche, D.J.O., Ray, L.A., Yardley, M.M. et al. Current Insights into the Mechanisms and Development of Treatments for Heavy-Drinking Cigarette Smokers. Curr Addict Rep 3, 125–137 (2016). https://doi.org/10.1007/s40429-016-0081-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40429-016-0081-3

Keywords

Search

Navigation